Abstract 322P
Background
There is limited evidence regarding the prognostic value of the three-tier chemotherapy response score (CRS) in advanced epithelial ovarian cancer (EOC). We aimed to evaluate the impact of CRS on survival in advanced EOC.
Methods
This prospective single-centre study included consecutive women with stage IIIC-IV EOC who underwent interval debulking surgery (IDS) after neoadjuvant chemotherapy (NACT) at Tata Medical Center between March 2021 and June 2022. Clinical characteristics, progression-free survival (PFS), and overall survival (OS) were compared between the CRS groups.
Results
Among the 102 women treated with NACT followed by IDS, CRS 1 was found in 16 (15.7%), CRS 2 in 66 (64.7%), and CRS 3 in 20 (19.6%). Age, stage, and BRCA status were not different across CRS groups. The patients with CRS 3 had significantly longer PFS than the other CRS groups (median PFS 17 months, 19.8 months, and not reached for CRS 1, 2, and 3, respectively, P = 0.001). Estimated OS was also significantly longer in those with CRS 3 (median OS 22.2 months, 33 months, and not reached for CRS 1, 2, and 3, respectively, P = 0.035). The PFS and OS differences remained statistically significant in univariate and multivariate analyses.
Conclusions
Chemotherapy response score 3 was associated with improved survival in advanced EOC treated with NACT. The prognostic value of CRS can be used in future studies of response-adapted adjuvant or maintenance treatment in advanced EOC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract